Arimidex ‘Highly Effective’ at Reducing Long-term Breast Cancer Rates in At-risk Women, Study Finds

Arimidex ‘Highly Effective’ at Reducing Long-term Breast Cancer Rates in At-risk Women, Study Finds
Postmenopausal women at increased risk of breast cancer are half as likely to develop the cancer after a five-year treatment with Arimidex (anastrozole), compared to a placebo, and this reduced likelihood holds for up to seven years after stopping the therapy, a long-term follow-up study has found. The findings suggest that Arimidex is a better preventive treatment for postmenopausal women than tamoxifen — which reduces cancer rates by 29% — and could replace it as the standard approach for this indication. The study, “Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial,” was published in The Lancet and simultaneously presented at the 2019 San Antonio Breast Cancer Symposium, in Texas. Because exposure to estrogen in postmenopausal women increases the risk of breast cancer, those at high risk are often offered preventive treatments that delay or prevent cancer from developing.  Pr
Subscribe or to access all post and page content.